Summary: Aetna, a CVS Health company, modified CPB 0865 covering romidepsin, effective April 18, 2026. Here's what changes for billing teams.
Aetna updated its romidepsin coverage policy under CPB 0865 as of April 18, 2026. Romidepsin is an IV chemotherapy agent used primarily for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). The policy does not list specific CPT or HCPCS codes in the available data — more on that below. If your oncology or hematology billing team submits claims for romidepsin infusions to Aetna, this modification is worth a close look before processing new claims.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Romidepsin — CPB 0865 |
| Policy Code | CPB 0865 |
| Change Type | Modified |
| Effective Date | April 18, 2026 |
| Impact Level | High |
| Specialties Affected | Oncology, Hematology, Infusion Therapy |
| Key Action | Review current romidepsin claims and prior authorization requirements against updated CPB 0865 criteria before submitting new claims |
Aetna Romidepsin Coverage Criteria and Medical Necessity Requirements 2026
Aetna's romidepsin coverage policy under CPB 0865 governs when the payer considers this drug medically necessary and reimbursable. Romidepsin — sold under the brand name Istodax — is an HDAC inhibitor approved by the FDA for two distinct lymphoma indications. The coverage criteria Aetna applies to romidepsin billing track closely with those FDA-approved indications, but payer criteria and FDA labeling don't always align perfectly.
The two core covered indications for romidepsin are CTCL in patients who have received at least one prior systemic therapy, and PTCL in patients who have received at least one prior therapy. Both are relapsed or refractory settings. Aetna's medical necessity review for romidepsin claims will typically require documentation of prior treatment failure, confirmed histologic diagnosis, and treating physician attestation that the drug is being used consistent with the approved indication.
Prior authorization is almost certainly required for romidepsin under Aetna plans. This is standard for specialty oncology drugs in this class, and CPB 0865 has historically required prior auth before the drug is administered. If you're billing for a romidepsin infusion without a confirmed prior authorization on file, you're looking at a claim denial regardless of what changed in the April 18, 2026 update.
The medical necessity bar for oncology drugs at Aetna has tightened across multiple CPBs over the past 18 months. This modification to CPB 0865 fits that pattern. When Aetna modifies an oncology CPB, it usually means one of three things: updated clinical evidence prompted a criteria revision, the off-label indications list changed, or documentation requirements got more specific. Without the full revised policy text available, your compliance officer should pull the current CPB 0865 from Aetna's website and compare it line-by-line against the version your team has been working from.
Aetna Romidepsin Exclusions and Non-Covered Indications
Romidepsin billing outside the two FDA-approved indications — CTCL and PTCL — puts you in experimental or investigational territory under most payer coverage policies. Aetna has historically classified off-label use of HDAC inhibitors for indications like Hodgkin lymphoma, AML, or other hematologic malignancies as not medically necessary unless supported by specific clinical trial evidence or NCCN Category 1/2A recommendations.
Combination regimens that include romidepsin alongside other chemotherapy agents for non-approved indications are particularly vulnerable to denial under CPB 0865. If your oncologists are using romidepsin in a combination protocol outside the labeled indication, that requires a stronger prior auth justification — and even then, Aetna may not cover it.
Use for solid tumors falls outside covered indications entirely. Aetna does not cover romidepsin for breast cancer, lung cancer, or other solid tumor histologies under this CPB. Claims submitted with diagnosis codes pointing to solid tumors will deny on medical necessity grounds.
Coverage Indications at a Glance
The available policy data for CPB 0865 does not include a specific coded indication list. The table below reflects the known indication framework based on the drug's approval history and Aetna's standard approach to HDAC inhibitor coverage policies. Confirm against the current CPB 0865 text before relying on this for billing decisions.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| CTCL — relapsed/refractory, ≥1 prior systemic therapy | Covered | ICD-10: C84.00–C84.09 (CTCL variants) | Prior authorization required; documentation of prior therapy failure needed |
| PTCL — relapsed/refractory, ≥1 prior therapy | Covered | ICD-10: C84.40–C84.49, C84.60–C84.69 (PTCL variants) | Prior authorization required; confirmed histologic diagnosis required |
| Off-label hematologic malignancies (e.g., Hodgkin lymphoma, AML) | Not Covered / Experimental | Varies | May be covered if supported by NCCN Category 1 or 2A recommendation — requires strong prior auth documentation |
| Solid tumor indications | Not Covered | N/A | Outside CPB 0865 scope entirely |
| Combination regimens outside labeled indications | Not Covered / Investigational | Varies | Prior auth will likely be denied without compelling clinical evidence |
Note: The policy does not list specific CPT or HCPCS codes in the available data. Codes above are based on known clinical indications. Verify against the full CPB 0865 text.
Aetna Romidepsin Billing Guidelines and Action Items 2026
The April 18, 2026 effective date has passed. If your team hasn't reviewed claims submitted around that date, start there. Here's what to do now.
| # | Action Item |
|---|---|
| 1 | Pull the updated CPB 0865 text from Aetna's clinical policy bulletin library. The modification happened April 18, 2026. Get the current version and compare it to the version your team has been using. Look specifically for changes to medical necessity criteria, prior authorization requirements, and covered indications. If you don't have a previous version, contact your Aetna provider relations rep and ask for the change summary. |
| 2 | Audit romidepsin claims submitted on or after April 18, 2026. Check that each claim was billed under a covered indication with appropriate documentation. Any claim that went out without a prior authorization confirmation — or with a diagnosis code outside the covered indication set — is at risk for denial. Pull those claims now before Aetna's adjudication catches them. |
| 3 | Confirm prior authorization is active for every in-progress romidepsin case. Don't assume a prior auth granted before April 18, 2026 is still valid under the updated criteria. Call Aetna to verify that existing authorizations cover the remaining treatment cycles. Some payers require reauthorization when a CPB is modified, even mid-course. |
| 4 | Update your documentation templates for romidepsin infusion orders. Your clinical documentation needs to show prior therapy failure, confirmed diagnosis (with histology), and physician attestation of medical necessity under the updated criteria. If your templates predate this modification, they may be missing elements Aetna now requires. Work with your medical director and compliance officer to revise them before the next prior auth submission. |
| 5 | Flag off-label romidepsin orders for enhanced review. Any order that falls outside CTCL or PTCL indications should go through your reimbursement review process before you bill. Aetna romidepsin billing for off-label use without solid prior auth documentation is a direct path to claim denial. If your physicians are using romidepsin off-label based on NCCN guidelines, make sure those NCCN citations are in the prior auth package. |
| 6 | Talk to your compliance officer if you're uncertain about the scope of changes. This is a modified policy, not a new one — but modifications to oncology drug CPBs can have real financial exposure. If your practice has significant romidepsin volume, a compliance review of your billing guidelines and authorization workflow is worth the time. Don't wait for a batch of denials to surface the problem. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Romidepsin Under CPB 0865
The available policy data for CPB 0865 does not list specific CPT or HCPCS codes. Do not rely on assumed codes for billing. Pull the full CPB 0865 document from Aetna's website to get the exact codes Aetna ties to this policy.
That said, romidepsin billing typically involves a specific HCPCS J-code for the drug itself, along with infusion administration codes. Your pharmacy and billing teams should confirm the correct J-code is active and mapped to CPB 0865 in your charge capture system. Using a stale or incorrect J-code is one of the most common reasons romidepsin claims deny at the line level — and it's entirely preventable.
For ICD-10 diagnosis coding, make sure the code on the claim matches the histologic subtype documented in the medical record. CTCL and PTCL each have multiple ICD-10 subcategories, and an imprecise code can trigger a medical necessity denial even when the underlying clinical picture supports coverage.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.